GlassScriptPhysician profile
Helen Dolan
NPI 1104098631
$14,362.61
in general payments reported to CMS, 2019-2025
50 companies · $3,654 in 2025
The $3,654 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,508 · 2022: $2,267 · 2023: $2,999 · 2024: $2,935 · 2025: $3,654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,587.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $2,505.53 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $2,433.60 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $1,176.49 | 2021-2025 | |
| Abbott Laboratories | $794.65 | 2022-2025 | Freestyle Libre 3 |
| Amgen INC. | $727.16 | 2021-2025 | Evenity, Tepezza, Prolia |
| Abbvie INC. | $656.92 | 2021-2025 | |
| Dexcom, INC. | $588.16 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Corcept Therapeutics | $512.06 | 2021-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $391.70 | 2021-2025 | |
| Tandem Diabetes Care, INC. | $363.12 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Radius Health, INC. | $329.80 | 2023-2025 | Tymlos |
| Alexion Pharmaceuticals, INC. | $326.17 | 2023-2025 | Strensiq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $282.84 | 2021-2025 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $263.67 | 2021-2025 | Farxiga |
| Mannkind Corporation | $254.83 | 2021-2025 | Afrezza |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $235.89 | 2024-2025 | Omnipod |
| Ibsa Pharma INC. | $220.37 | 2021-2025 | Tirosint, Tirosint, Licart |
| Glaxosmithkline, LLC. | $213.31 | 2021-2023 | Trelegy Ellipta |
| Recordati_rare_diseases_inc. | $194.58 | 2023-2025 | Isturisa, Signifor Lar |
| Medtronic, INC. | $179.08 | 2023-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Tolmar, INC. | $158.59 | 2023-2025 | Jatenzo |
| Pfizer INC. | $147.55 | 2022-2025 | |
| Astellas Pharma US INC | $135.75 | 2023-2025 | Veozah, Myrbetriq |
| Verona Pharma, INC. | $123.05 | 2025 | Ohtuvayre |
| Amneal Pharmaceuticals LLC | $114.16 | 2023-2025 | Unithroid |
| Averitas Pharma INC. | $106.73 | 2025 | Qutenza |
| Novartis Pharmaceuticals Corporation | $95.06 | 2021-2022 | |
| Ascendis Pharma Endocrinology INC | $91.41 | 2024-2025 | Yorvipath |
| Merck Sharp & Dohme LLC | $86.26 | 2021-2023 | Steglujan, Steglatro |
| Ultragenyx Pharmaceutical INC. | $84.11 | 2021-2024 | Crysvita |
| Antares Pharma, INC. | $73.96 | 2023-2024 | Xyosted, Tlando, Nocdurna |
| Sandoz INC. | $66.31 | 2025 | Jubbonti |
| Amphastar Pharmaceuticals, INC. | $50.69 | 2025 | |
| Chiesi USA, INC. | $43.42 | 2024-2025 | Mycapssa |
| Madrigal Pharmaceuticals | $36.92 | 2025 | Rezdiffra |
| Amryt Pharma Holdings LTD | $29.81 | 2023 | Mycapssa |
| Almatica Pharma LLC | $27.99 | 2025 | Teriparatide |
| Sequel Med Tech, LLC | $23.32 | 2025 | Twiist |
| Rhythm Pharmaceuticals, INC. | $21.89 | 2025 | Imcivree |
| Teva Pharmaceuticals USA, INC. | $21.40 | 2025 | Austedo Xr |
| Biohaven Pharmaceuticals, INC. | $20.43 | 2021 | |
| Halozyme INC | $20.42 | 2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.20 | 2022 | |
| Indivior INC. | $18.00 | 2021 | |
| Xeris Pharmaceuticals, INC. | $17.66 | 2022 | |
| Boston Scientific Corporation | $17.45 | 2021 | |
| Soleno Therapeutics, INC. | $16.20 | 2025 | Vykat Xr |
| Esperion Therapeutics, INC. | $15.54 | 2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $14.72 | 2021 | |
| Avanir Pharmaceuticals, INC. | $14.68 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helen Dolan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.